NCT01559935 · REGISTRY CONDITION SEARCH

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2026-08-19

The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment with a combination of drugs clarithromycin (Biaxin®), lenalidomide (Revlimid®) and dexamethasone (Decadron®) \[BiRD\] then lenalidomide alone.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Response to Car-BiRD Treatment.

→

outcome · POSTED

Event Free Survival

→

outcome · POSTED

MRD Negativity Following CarBiRD Regimen

→

outcome · POSTED

Progression Free Survival

→

outcome · POSTED

Stem Cells Collection

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Subject must voluntarily sign and understand written informed consent. * Subject is ≥ 18 years at the time of signing the consent form. * Subject has histologically confirmed multiple myeloma that has never before been treated. * Subject had no anti-myeloma therapy within 14 days prior to initiation of study treatment except for corticosteroids with a maximum allowed dosage equivalent to three pulses of dexamethasone (40mg daily for 4 days equals one pulse). Patients may have received prior adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine care, or radiation therapy as palliation for pain and/or spinal cord compression. * Subject has measurable disease as defined by \> 0.5 g/dL serum monoclonal protein, \> 10 mg/dL involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, \> 0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either CT scanning or MRI. * Subject has a Karnofsky performance status ≥ 60% (\> 50% if due to bony involvement of myeloma (see Appendix VI). * Subject is able to take prophylactic anticoagulation as detailed in section 9.1 (patients intolerant to aspirin may use warfarin or low molecular weight heparin). * Subject is registered into the mandatory RevAssist® program, and is willing and able to comply with the requirements of RevAssist® program. * If subject is a female of childbearing potential (FCBP),† she must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with females of child bearing potential even if they have had a successful vasectomy. * Subjects must meet the following laboratory parameters: * Absolute neutrophil count (ANC) ≥750 cells/mm3 (1.0 x 109/L) * Hemoglobin ≥ 7 g/dL * Platelet count ≥ 30,000/mm3 (75 x 109/L) * Serum SGOT/AST \< 3.0 x upper limits of normal (ULN) * Serum SGPT/ALT \< 3.0 x upper limits of normal (ULN) * Serum creatinine \< 2.5 mg/dL (221 µmol/L) * Serum total bilirubin \< 2.0 mg/dL (34 µmol/L) Exclusion Criteria: * Subject has immeasurable MM (no measurable monoclonal protein, free light chains in blood or urine, or measureable plasmacytoma on radiologic scanning). * Subject has a prior history of other malignancies unless disease free for ≥ 5 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or localized prostate cancer with Gleason score \< 7 with stable prostate specific antigen (PSA) levels. * Subject has had myocardial infarction within 6 months prior to enrollment , or NYHA(New York Hospital Association) Class III or IV heart failure, Ejection Fraction \< 35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities. * Female subject who is pregnant or lactating. * Subject has known HIV infection * Subject has known active hepatitis B or hepatitis C infection. * Subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program. * Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, thalidomide, allopurinol, or carfilzomib. * Subject has a history of thromboembolic event within the past 4 weeks prior to enrollment. * Subject has any clinically significant medical or psychiatric disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) \[Car-BiRD\]
intervention Names
Drug: carfilzomib
Drug: Dexamethasone
Drug: Clarithromycin
Drug: Lenalidomide
label
Car-BiRD Therapy
type
EXPERIMENTAL

interventions

arm Group Labels
Car-BiRD Therapy
description
45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
name
carfilzomib
type
DRUG
arm Group Labels
Car-BiRD Therapy
description
20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
name
Dexamethasone
other Names
DECADRON®
type
DRUG
arm Group Labels
Car-BiRD Therapy
description
500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
name
Clarithromycin
other Names
Biaxin
type
DRUG
arm Group Labels
Car-BiRD Therapy
description
25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
name
Lenalidomide
other Names
Revlimid
type
DRUG
arm Group Labels
Car-BiRD Therapy
description
40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
name
Dexamethasone
type
DRUG
arm Group Labels
Car-BiRD Therapy
description
10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
name
Lenalidomide
other Names
Revlimid
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 74
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The best response for all patients who had at least one dose of drug was measured. Response categories: Stringent Complete Response (sCR), Complete Remission(CR), Very Good Partial Remission(VGPR), Partial Remission (PR), Progressive Disease (PD), Stable Disease (SD). The response is evaluated based on the IMWG criteria.
measure
Response to Car-BiRD Treatment.
time Frame
From baseline to best response, up to 116 weeks.

secondary Outcomes

description
an event is defined by coming off protocol for any reason, including progression of disease, lack of disease response, regimen intolerability, withdrawal of consent or death.
measure
Event Free Survival
time Frame
From date of study enrollment until the date of removal of study due to progression of disease, toxicity or withdrawal of consent, up to 1222 days.
description
Minimal Residual Disease (MRD) was assessed for all participants as soon as they achieved CR/sCR, regardless of what phase they were on. MRD negativity is defined as the complete absence of plasma cells on bone marrow biopsy. MRD positivity is defined as the presence of residual plasma cells (\<5%) on bone marrow biopsy. The IMWG criteria were used to determine CR and sCR.
measure
MRD Negativity Following CarBiRD Regimen
time Frame
From start of study up to Revlimid Maintenance Cycle 4.
description
Progression was defined using the IMWG criteria.
measure
Progression Free Survival
time Frame
From start of study drug until first incidence of progression, up to 1222 days.
description
At the end of the Car Phase, all participants underwent stem cell collection.
measure
Stem Cells Collection
time Frame
At the end of the Car Phase, prior to the start of the BiRD Phase, on average after 162 days.

Full study description

brief Summary: The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment with a combination of drugs clarithromycin (Biaxin®), lenalidomide (Revlimid®) and dexamethasone (Decadron®) \[BiRD\] then lenalidomide alone.
detailed Description: While new anti-myeloma therapies such as bortezomib and immunomodulatory drugs have been developed, multiple myeloma remains an incurable malignancy. Given that obtaining a complete remission (CR) with therapy will allow patients with newly diagnosed multiple myeloma to enjoy a higher quality of life and longer duration of freedom from disease symptoms, finding an optimally effective and well-tolerated regimen is imperative. The robust overall response rate of 91% with the BiRD regimen for patients with newly diagnosed multiple myeloma is encouraging and we believe that by adding carfilzomib the overall response rate and CR rate can be improved. As carfilzomib has proven efficacy in myeloma and in patient's who have relapsed on bortezomib, we anticipate that it will synergize with the previous BiRD regimen to induce greater reduction of tumor burden overall. The primary endpoints include best response rate, toxicities, progression free survival, event free survival, and overall survival. In those patients who are eligible for autologous stem cell transplantation, we will also study the effect of carfilzomib on CD 34+ stem cell yield following mobilization.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-1eb11bdbf2ef61393476
requested nct id
NCT01559935
primary nct id
NCT01559935
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
f6c9169981699683a895e20a6ed66ec0944d5bbf9d957dddff235da89b831879
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-1eb11bdbf2ef61393476
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01559935
occurrences
context exact
NCT01559935
end
11
exact text
NCT01559935
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/278/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
a0bcf532c62c8745665d2559752d67e37e23b47b730e45a242bc522e86c4a473
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice